| Name | Title | Contact Details |
|---|---|---|
Harris Rotman |
Senior Vice President of Regulatory Affairs | Profile |
Kindred Pharmacy Services(Pmc Pharmacy Services ) is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.
With over 1,975 employees, it has a presence, through its 13 affiliates in Europe and United States.
Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.